Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (925) Arrow Down
Filter Results: (925) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,281)
    • People  (5)
    • News  (172)
    • Research  (925)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (758)

Show Results For

  • All HBS Web  (1,281)
    • People  (5)
    • News  (172)
    • Research  (925)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (758)
← Page 36 of 925 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • February 2005 (Revised April 2006)
  • Case

Rx Depot: Importing Drugs from Canada

By: Debora L. Spar
In 2002, a handful of entrepreneurs began to ship drugs from Canada into the United States, taking advantage of regulatory and price differentials across the neighboring countries. Using the Internet and a low-cost network of Canadian pharmacies, firms like Rx Depot... View Details
Keywords: Courts and Trials; Entrepreneurship; Intellectual Property; Laws and Statutes; Pharmaceutical Industry; Canada; United States
Citation
Find at Harvard
Related
Spar, Debora L., and Adam Day. "Rx Depot: Importing Drugs from Canada." Harvard Business School Case 705-010, February 2005. (Revised April 2006.)
  • 2003
  • Chapter

La tragédie de la thalidomide: affaires judiciaries et résponses législatives, 1959-1971

By: Arthur A. Daemmrich
Keywords: History; Courts and Trials; Government Legislation; Health Disorders; Pharmaceutical Industry
Citation
Related
Daemmrich, Arthur A. "La tragédie de la thalidomide: affaires judiciaries et résponses législatives, 1959-1971." In La médicine expérimentale au tribunal, edited by Christian Bonah, Etienne Lepicard, and Volker Roelcke, 291–318. Éditions des archives contemporaines, 2003.
  • May 2002 (Revised October 2005)
  • Case

Marketing Antidepressants: Prozac and Paxil

By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details
Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)
  • April 2002
  • Supplement

Grey Warner, Merck Latin America

By: Michael Beer
Grey Warner, the vice president of Merck's Latin America region, discusses the challenges raised in the case and the lessons learned. View Details
Keywords: Strategic Planning; Values and Beliefs; Change Management; Problems and Challenges; Management Teams; Pharmaceutical Industry; Latin America
Citation
Purchase
Related
Beer, Michael. "Grey Warner, Merck Latin America." Harvard Business School Video Supplement 402-801, April 2002.
  • February 2001 (Revised July 2006)
  • Case

Discovering the Future: R&D Strategy at Merck

By: Gary P. Pisano
Given explosive growth in technologies for drug discovery, how does Merck remain competitive in an industry that is fragmented and continues to consolidate? View Details
Keywords: Competitive Strategy; Research and Development; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Pisano, Gary P. "Discovering the Future: R&D Strategy at Merck." Harvard Business School Case 601-086, February 2001. (Revised July 2006.)
  • May 1987
  • Teaching Note

Eli Lilly and Co. (A) and (B), Teaching Note

By: William J. Bruns Jr.
Keywords: Pharmaceutical Industry
Citation
Related
Bruns, William J., Jr. "Eli Lilly and Co. (A) and (B), Teaching Note." Harvard Business School Teaching Note 187-186, May 1987.
  • June 1999 (Revised October 1999)
  • Case

Eli Lilly, 1998 (A): Strategic Challenges

By: Michael Y. Yoshino and Thomas W. Malnight
Deals with key strategic challenges facing Eli Lilly, a highly successful U.S.-based drug company. View Details
Keywords: Problems and Challenges; Strategy; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Yoshino, Michael Y., and Thomas W. Malnight. "Eli Lilly, 1998 (A): Strategic Challenges." Harvard Business School Case 399-173, June 1999. (Revised October 1999.)
  • June 1998
  • Supplement

MBA Integrative Exercise: Competition & Strategy, April 1998 , Video

By: Carin-Isabel Knoop
Daniel Vasella, President of Novartis AG, discusses the situation in Indonesia and his ideas of what Suharto should do in the spring of 1998. Drummond Paris, Regional Pharma Head Asia/Pacific, Novartis AG, discusses the opportunities for Novartis in Indonesia and also... View Details
Keywords: Competitive Strategy; Pharmaceutical Industry; Indonesia
Citation
Purchase
Related
Knoop, Carin-Isabel. "MBA Integrative Exercise: Competition & Strategy, April 1998 , Video." Harvard Business School Video Supplement 898-504, June 1998.
  • March 1993
  • Supplement

Burroughs Wellcome and AZT (C)

By: Willis M. Emmons III
Describes key developments relating to Burroughs Wellcome, AZT and other AIDS drugs, and the AIDS issue in general from late 1989 through 1992. Includes excerpts from Wellcome PLC's financial statements and updated statistics on AIDS in the United States. View Details
Keywords: Health Pandemics; Multinational Firms and Management; Financial Statements; Pharmaceutical Industry; United States
Citation
Purchase
Related
Emmons, Willis M., III. "Burroughs Wellcome and AZT (C)." Harvard Business School Supplement 793-115, March 1993.
  • March 1993
  • Supplement

Burroughs Wellcome and AZT (B)

By: Willis M. Emmons III
Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details
Keywords: Ethics; Health Pandemics; Multinational Firms and Management; Price; Crime and Corruption; Risk and Uncertainty; Business Strategy; Business and Community Relations; Business and Government Relations; Business and Shareholder Relations; Pharmaceutical Industry
Citation
Purchase
Related
Emmons, Willis M., III. "Burroughs Wellcome and AZT (B)." Harvard Business School Supplement 793-114, March 1993.
  • March 1997
  • Teaching Note

Eli Lilly and Company: Innovation in Diabetes Care TN

By: Clayton M. Christensen and Bret J. Baird
Teaching Note for (9-696-077). View Details
Keywords: Pharmaceutical Industry
Citation
Purchase
Related
Christensen, Clayton M., and Bret J. Baird. "Eli Lilly and Company: Innovation in Diabetes Care TN." Harvard Business School Teaching Note 697-101, March 1997.
  • December 1998 (Revised September 1999)
  • Case

Novartis: Betting on Life Sciences

By: Ray A. Goldberg, Carin-Isabel Knoop and Srinivas Sunder
The merger of Ciba-Geigy and Sandoz produced genomic-based synergies for health care, agribusiness, and nutritional supplements. How to build on the strength of the individual divisions and provide synergies that would continue Novartis' leadership role is the question... View Details
Keywords: Mergers and Acquisitions; Business Divisions; Health Care and Treatment; Leadership; Product Positioning; Science-Based Business; Corporate Strategy; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Goldberg, Ray A., Carin-Isabel Knoop, and Srinivas Sunder. "Novartis: Betting on Life Sciences." Harvard Business School Case 599-076, December 1998. (Revised September 1999.)
  • January–February 1994
  • Article

Financial Engineering at Merck

By: Timothy A. Luehrman
Keywords: Finance; Engineering; Health; Pharmaceutical Industry
Citation
Find at Harvard
Related
Luehrman, Timothy A. "Financial Engineering at Merck." Harvard Business Review 72, no. 1 (January–February 1994): 89–99.
  • November 18 2004
  • Article

Merck's Recall of Rofecoxib: A Strategic Perspective

By: Felix Oberholzer-Gee and Noorein Inamdar
Keywords: Health; Perspective; Pharmaceutical Industry
Citation
Find at Harvard
Related
Oberholzer-Gee, Felix, and Noorein Inamdar. "Merck's Recall of Rofecoxib: A Strategic Perspective." New England Journal of Medicine 351, no. 21 (November 18 2004): 2147–2149.
  • April 1999 (Revised May 2000)
  • Case

Pilgrim Drug Company

David Thomas takes his first sales management assignment and is faced with a sales rep revolt because of a possible territory reorganization. In addition, his sales division is performing well below the national average. Rewritten version of an earlier case. View Details
Keywords: Conflict Management; Salesforce Management; Performance; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Burton, M. Diane, and Jeffrey L. Bradach. "Pilgrim Drug Company." Harvard Business School Case 499-062, April 1999. (Revised May 2000.)
  • February 26, 2003
  • Article

Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising

By: Joel S. Weissman, David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman and Robert Leitman
Keywords: Customers; Advertising; Health; Pharmaceutical Industry
Citation
Find at Harvard
Read Now
Related
Weissman, Joel S., David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman, and Robert Leitman. "Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising." Health Affairs (February 26, 2003).
  • 01 Dec 2003
  • Research & Ideas

Sometimes Success Begins at Failure

In the late 1980s, scientists for New York City-based drug-maker Pfizer began testing what was then known as compound UK-92,480 for the treatment of angina. Although UK-92,480 seemed promising in the lab and in animal tests, the compound showed little benefit in... View Details
Keywords: by Henry Chesbrough; Pharmaceutical; Pharmaceutical
  • January 1975 (Revised May 1983)
  • Case

CIBA-GEIGY Corp. (B)

By: Malcolm S. Salter
Keywords: Pharmaceutical Industry
Citation
Find at Harvard
Related
Salter, Malcolm S. "CIBA-GEIGY Corp. (B)." Harvard Business School Case 375-247, January 1975. (Revised May 1983.)
  • 2001
  • Case

SmithKline Beecham (SB)

By: R. Lal
Keywords: Pharmaceutical Industry
Citation
Related
Lal, R. "SmithKline Beecham (SB)." 2001.
  • January 1992
  • Teaching Note

Advanced Medical Technology Corporation TN

By: Thomas R. Piper
Teaching Note for (9-287-028). View Details
Keywords: Pharmaceutical Industry
Citation
Purchase
Related
Piper, Thomas R. "Advanced Medical Technology Corporation TN." Harvard Business School Teaching Note 292-054, January 1992.
  • ←
  • 36
  • 37
  • …
  • 46
  • 47
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.